Science Pirtobrutinib Shows Promise in BTK Inhibitor Comparisons Recent analyses have highlighted the efficacy and safety profiles of pirtobrutinib, a novel non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. The discussions, led by oncology... Editorial13 January, 2026